Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day-to-day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US-focused expert clinical decision-making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration-resistant prostate cancer; poly [ADP-ribose] polymerase inhibitors; prostate-specific membrane antigen radioligand therapy; and metastatic, castration-resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.
Cancer. 2024 Dec 01 [Epub ahead of print]
Alan H Bryce, Neeraj Agarwal, Himisha Beltran, Maha H Hussain, Oliver Sartor, Neal Shore, Emmanuel S Antonarakis, Andrew J Armstrong, Jeremie Calais, Michael A Carducci, Tanya Barauskas Dorff, Jason A Efstathiou, Martin Gleave, Leonard G Gomella, Celestia Higano, Thomas A Hope, Andrei Iagaru, Alicia K Morgans, David S Morris, Michael J Morris, Daniel P Petrylak, Robert E Reiter, Matthew B Rettig, Charles J Ryan, Scott B Sellinger, Daniel E Spratt, Sandy Srinivas, Scott T Tagawa, Mary-Ellen Taplin, Evan Y Yu, Tian Zhang, Rana R McKay, Phillip J Koo, E David Crawford
Department of Medical Oncology and Therapeutics Research, City of Hope Phoenix, Phoenix, Arizona, USA., Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA., Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, Illinois, USA., Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA., Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA., Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA., Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA., Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California, USA., Hopkins Kimmel Cancer Center, Baltimore, Maryland, USA., City of Hope Comprehensive Cancer Center, Duarte, California, USA., Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Urological Sciences, Vancouver Prostate Center, University of British Columbia, Vancouver, British Columbia, Canada., Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Madrona Oncology, Seattle, Washington, USA., Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA., Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California, USA., Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Urology Associates PC, Nashville, Tennessee, USA., Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Yale New Haven Health, New Haven, Connecticut, USA., Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, USA., Division of Hematology-Oncology, Department of Medicine, VA Greater Los Angeles, Los Angeles, California, USA., Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA., Advanced Urology Institute, Tallahassee, Florida, USA., University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA., Division of Medical Oncology, Stanford University Medical Center, Stanford, California, USA., Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, USA., Division of Hematology and Oncology, Department of Medicine, University of Washington and Fred Hutchinson Cancer Center, Seattle, Washington, USA., Division of Hematology and Oncology, Department of Internal Medicine, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA., Department of Urology, University of California San Diego, La Jolla, California, USA., Banner MD Anderson Cancer Center, Phoenix, Arizona, USA.